{"schema_version":"secwatch.filing_event.v1","accession":"0001000694-25-000031","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.099661+00:00","generated_at":"2026-05-17T18:48:01.750313+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Novavax Q2 revenue $239M; net income $107M; $175M Sanofi milestone from FDA BLA approval","bullets":["Total revenue of $239M, down 42% YoY, includes $175M milestone from Nuvaxovid BLA approval.","Net income of $107M vs $162M YoY; cash $628M; $175M milestone receipt expected Q3 2025.","Updated FY2025 adjusted total revenue guidance to $1,000-1,050M (prior $975-1,025M).","Combined R&D/SG&A expense guidance raised to $495-545M; includes $20M postmarketing study cost.","Phase 3 data for COVID-flu combo and standalone flu candidates showed robust immune responses."],"urls":{"canonical":"https://secwatch.observer/filing/0001000694-25-000031","json":"https://secwatch.observer/filing/0001000694-25-000031.json","markdown":"https://secwatch.observer/filing/0001000694-25-000031.md","text":"https://secwatch.observer/filing/0001000694-25-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000100069425000031/0001000694-25-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000100069425000031/nvax-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:48:01.750313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}